Search

everythinglearnresearchcommunity

for

Search:↓

Most patients with alopecia areata in China have patchy hair loss, with total hair loss being less common, and the condition often starts around age 35 and can negatively affect quality of life, especially in more severe cases.

Alopecia areata has different forms and can significantly affect quality of life, especially in more severe cases.

The study concluded that patients with total hair loss and recurring hair loss had an earlier onset, longer-lasting condition, and a greater negative impact on their quality of life, with allergic conditions linked to more severe hair loss.

Alopecia areata in infants may be more common than previously thought.

Low iron levels may be linked to some types of hair loss in women.

Alopecia Areata has no cure, treatments are limited, and the condition often recurs, but new therapies like JAK inhibitors show promise.

The study found that severe alopecia areata affects any age, treatments often give temporary results, and some factors predict worse outcomes.

People with certain allergic conditions or higher white blood cell counts have more severe hair loss, and treating hair and nail side effects early in melanoma therapy can improve quality of life.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.

Alopecia areata is an autoimmune condition causing patchy hair loss, with treatments focusing on immune system regulation and hair regrowth.

Tofacitinib is an effective and safe treatment for alopecia areata.

Modern treatments can effectively regrow hair and improve life for people with alopecia areata.

Alopecia areata causes hair loss with varied treatment responses and frequent relapses.

Alopecia areata can sometimes appear as a straight line of hair loss instead of round patches.

Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

Diphenylcyclopropenone is effective for treating alopecia areata but has a high relapse rate.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

A new mix of anthralin and calcipotriene might help treat severe hair loss.

Bexarotene gel shows promise as a new treatment for alopecia areata.

People with alopecia areata often have thyroid autoimmunity.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Baricitinib improved hair loss and arthritis in a lupus patient.

The treatment is effective and safe for severe alopecia areata in children, but not for total or universal hair loss.

An 11-year-old girl with severe hair loss was successfully treated with a new combination therapy.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

Most patients with small patches of hair loss usually regrow hair.

Alopecia areata was most common in people in their 30s and 40s, with some family history and a higher relapse rate, and larger bald areas responded better to specific immunotherapy.

Corticosteroids are the most common treatment for alopecia areata, but many patients need better options.